Vytorin/Zetia Rx Decline Prompts Schering-Plough To Issue Monthly Updates
Executive Summary
Schering-Plough says it will soon start providing monthly updates on prescription rates for its two cholesterol drugs Vytorin (ezetimibe/simvastatin) and Zetia (ezetimibe) to help ease the minds of anxious investors
You may also be interested in...
Medco Downplays Competition From Health Plans’ In-House PBMs
Pharmacy benefit manager subsidiaries of large health insurers lack the scale and capability to provide the kinds of cost benefits and services offered by the big stand-alone PBMs, Medco Health Solutions Chairman David Snow maintains
Medco Downplays Competition From Health Plans’ In-House PBMs
Pharmacy benefit manager subsidiaries of large health insurers lack the scale and capability to provide the kinds of cost benefits and services offered by the big stand-alone PBMs, Medco Health Solutions Chairman David Snow maintains
Schering-Plough Says Organon Deal Offers Key To Women’s Health Market
Schering-Plough is looking to build a presence in the women's health care market with the integration of Organon Biosciences